EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study

Giannis Mountzios, Julius K Weng, Eleni Zairi, Kristin Hsieh, Pratibha Chander, William Dunlop, Yao Qiao, Alice Wang, Adam Januszewski

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Giannis Mountzios und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece. Electronic address: gmountzios@gmail.co…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Lung Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Many patients with unresectable stage III non-small-lung cancer (NSCLC) may face challenges in receiving consolidation durvalumab following concurrent chemoradiotherapy (cCRT) due to incomplete cCRT or disease progression. The retrospective POSITION study characterized this population. METHODS: Adults with unresectable stage III NSCLC diagnosed between 2010 and 2021 who received cCRT were identified from TEMPUS Oncology (database). Among these patients, we estimated proportions with incomplete cCRT or progression during/within 42 days of cCRT and assessed overall survival (OS). Factors associated with incomplete cCRT or progression during/within 42 days of cCRT were identified via multivariable logistic regression. RESULTS: Of 2076 eligible patients, 23.0% had incomplete cCRT (Group A), 12.7% experienced progression during/within 42 days of cCRT (Group B), and 64.3% completed cCRT without progression (Group C). Median OS (95% CI) was 21.6 (17.2-28.0), 10.1 (7.2-12.5), and 32.4 (29.8-34.6) months for Groups A, B, and C, respectively. Landmark 60-month OS rates were 26.3%, 11.6% and 33.2% for Groups A, B and C, respectively. Higher comorbidity burden (Charlson Comorbidity Index) and Black (vs. White) race were associated with higher likelihood of incomplete cCRT. Stage IIIB/C (vs. IIIA), cerebrovascular, and renal disease were associated with higher likelihood of progression during/within 42 days of cCRT. CONCLUSION: In POSITION, 35.7% of patients had incomplete cCRT or progressed during/within 42 days of cCRT and may have faced challenges receiving consolidation durvalumab; race, disease stage, and comorbidities were associated with incomplete cCRT or progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsHumansMaleRetrospective StudiesFemaleDisease ProgressionRisk FactorsNeoplasm StagingAgedMiddle AgedAntibodies, MonoclonalSurvival Rate

Stichwörter der Autor:innen

Consolidation therapyLocally advanced NSCLCPACIFIC regimenReal-world dataRisk factors

Substanzen

Antibodies, Monoclonaldurvalumab

Autor:innen und Institutionen

  • Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece. Electronic address: gmountzios@gmail.com.
  • Department of Radiation Oncology, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, CA.
  • Medical Oncology Department, St. Luke's Hospital, Thessaloniki, Greece; Fourth Department of Medical Oncology and Clinical Trials Unit, International Oncology Center, European Interbalkan Medical Center, Thessaloniki, G…
  • Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York Proton Center, New York, NY.
  • AstraZeneca, Gaithersburg, MD.
  • AstraZeneca, Cambridge, UK.

Förderung

  • AstraZeneca

Zitieren

APA

Mountzios, G., Weng, J. K., Zairi, E., Hsieh, K., Chander, P., Dunlop, W., Qiao, Y., Wang, A., & Januszewski, A. (2026). Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.01.005

Vancouver

Mountzios G, Weng JK, Zairi E, Hsieh K, Chander P, Dunlop W, et al. Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.01.005

BibTeX
@article{Mountzios2026,
  author = {Mountzios, Giannis and Weng, Julius K and Zairi, Eleni and Hsieh, Kristin and Chander, Pratibha and Dunlop, William and Qiao, Yao and Wang, Alice and Januszewski, Adam},
  title = {Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.01.005}
}
Kostenlos starten →